On 11 November 2026, the European Commission’s Directorate-General for Health and Food Safety (DG SANTE), the European Medicines Agency (EMA) and Singapore’s Health Sciences Authority (HSA) formally signed a Working Arrangement to further strengthen cooperation in public health, pharmaceuticals and medical device regulation.
The cooperation aims to promote regulatory information exchange, expert collaboration and regulatory science capacity building, supporting access to safe, high-quality medical products.
Official source:
1. Three Key Areas of Cooperation
1.1 Strengthening Regulatory Information Exchange
The two sides will exchange information in the following areas:
- Safety, effectiveness and quality of medical products;
- Authorisation of clinical trials;
- Product labelling;
- Regulatory policy development.
1.2 Strengthening Collaboration Among Regulatory Experts
The two sides will promote the participation of observers and experts in each other’s scientific committees, multilateral regulatory procedures and regulatory cluster activities, fostering the exchange of regulatory experience and professional capacity building.
1.3 Training and Knowledge Sharing
Through training and the sharing of expertise, the cooperation will enhance regulatory science capacity and promote the development of regulatory best practices on both sides.
2. When Does the Working Arrangement Take Effect?
According to information published by the European Commission:
- Effective date: applicable with immediate effect from 11 November 2026;
- Review mechanism: the Working Arrangement will be reviewed periodically;
- Adjustment mechanism: the two sides may consult each other to extend or adjust the Working Arrangement.
3. Impact on Medical Device Companies
This cooperation will further strengthen the exchange between the EU and Singapore on medical device safety, quality, clinical trials and regulatory policy.
For medical device companies operating in both the EU and Singapore markets, it is advisable to follow up closely on the specific progress of regulatory information exchange and cooperation mechanisms.
It should be noted that this Working Arrangement is a cooperation mechanism between regulatory authorities and does not provide for mutual recognition of medical device registrations, direct substitution of CE certification for HSA registration, or simplified registration and approval requirements. Companies must still comply separately with the current regulations of the EU and Singapore when seeking registration.